The prognostic significance of the presence of tenascin-C in patients with stable coronary heart disease

Sing Kong Ho; Hsin Bang Leu; Chau Chung Wu; Hung I. Yeh; Wei Hsian Yin; Tsung Hsien Lin; Kuan Cheng Chang; Ji Hung Wang; Wei Kung Tseng; Jaw Wen Chen; Yen Wen Wu

doi:10.1016/j.cca.2022.08.003

The prognostic significance of the presence of tenascin-C in patients with stable coronary heart disease

Sing Kong Ho, Hsin Bang Leu, Chau Chung Wu, Hung I. Yeh, Wei Hsian Yin, Tsung Hsien Lin, Kuan Cheng Chang, Ji Hung Wang, Wei Kung Tseng, Jaw Wen Chen, Yen Wen Wu

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Background: We investigated the prognostic value of tenascin-C in patients with stable coronary heart disease. Methods: A total of 666 patients were enrolled and followed for 72 months. The primary outcome was a composite of cardiac events. The secondary outcomes were all-cause death, cardiovascular death, acute myocardial infarction (AMI), and heart failure hospitalization. Results: The area under the curve of tenascin-C to discriminate the occurrence of composite cardiac events was 70 % (95 % CI: 64.2 % to 75.8 %), and the corresponding optimal cutoff value was 19.91 ng/ml. A higher concentration of tenascin-C was associated with a greater risk of composite cardiac events (P trend < 0.001). Similar results were observed in all-cause death, AMI, and heart failure hospitalization. Conclusion: Tenascin-C was found to be an independent predictor of total cardiovascular events in patients with stable coronary heart disease at 72 months, and also for all-cause death, AMI, and heart failure hospitalization.

Original language	English
Pages (from-to)	68-74
Number of pages	7
Journal	Clinica Chimica Acta
Volume	535
DOIs	https://doi.org/10.1016/j.cca.2022.08.003
Publication status	Published - Oct 1 2022
Externally published	Yes

Keywords

Acute myocardial infarction
Biomarker
Cardiovascular outcome
Stable coronary heart disease
Tenascin-C

ASJC Scopus subject areas

Biochemistry
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1016/j.cca.2022.08.003

Cite this

@article{db19ca18679949e2865b15eb60678871,

title = "The prognostic significance of the presence of tenascin-C in patients with stable coronary heart disease",

abstract = "Background: We investigated the prognostic value of tenascin-C in patients with stable coronary heart disease. Methods: A total of 666 patients were enrolled and followed for 72 months. The primary outcome was a composite of cardiac events. The secondary outcomes were all-cause death, cardiovascular death, acute myocardial infarction (AMI), and heart failure hospitalization. Results: The area under the curve of tenascin-C to discriminate the occurrence of composite cardiac events was 70 % (95 % CI: 64.2 % to 75.8 %), and the corresponding optimal cutoff value was 19.91 ng/ml. A higher concentration of tenascin-C was associated with a greater risk of composite cardiac events (P trend < 0.001). Similar results were observed in all-cause death, AMI, and heart failure hospitalization. Conclusion: Tenascin-C was found to be an independent predictor of total cardiovascular events in patients with stable coronary heart disease at 72 months, and also for all-cause death, AMI, and heart failure hospitalization.",

keywords = "Acute myocardial infarction, Biomarker, Cardiovascular outcome, Stable coronary heart disease, Tenascin-C",

author = "{Kong Ho}, Sing and Leu, {Hsin Bang} and Wu, {Chau Chung} and Yeh, {Hung I.} and Yin, {Wei Hsian} and Lin, {Tsung Hsien} and Chang, {Kuan Cheng} and Wang, {Ji Hung} and Tseng, {Wei Kung} and Chen, {Jaw Wen} and Wu, {Yen Wen}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/j.cca.2022.08.003",

language = "English",

volume = "535",

pages = "68--74",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

}

TY - JOUR

T1 - The prognostic significance of the presence of tenascin-C in patients with stable coronary heart disease

AU - Kong Ho, Sing

AU - Leu, Hsin Bang

AU - Wu, Chau Chung

AU - Yeh, Hung I.

AU - Yin, Wei Hsian

AU - Lin, Tsung Hsien

AU - Chang, Kuan Cheng

AU - Wang, Ji Hung

AU - Tseng, Wei Kung

AU - Chen, Jaw Wen

AU - Wu, Yen Wen

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Background: We investigated the prognostic value of tenascin-C in patients with stable coronary heart disease. Methods: A total of 666 patients were enrolled and followed for 72 months. The primary outcome was a composite of cardiac events. The secondary outcomes were all-cause death, cardiovascular death, acute myocardial infarction (AMI), and heart failure hospitalization. Results: The area under the curve of tenascin-C to discriminate the occurrence of composite cardiac events was 70 % (95 % CI: 64.2 % to 75.8 %), and the corresponding optimal cutoff value was 19.91 ng/ml. A higher concentration of tenascin-C was associated with a greater risk of composite cardiac events (P trend < 0.001). Similar results were observed in all-cause death, AMI, and heart failure hospitalization. Conclusion: Tenascin-C was found to be an independent predictor of total cardiovascular events in patients with stable coronary heart disease at 72 months, and also for all-cause death, AMI, and heart failure hospitalization.

AB - Background: We investigated the prognostic value of tenascin-C in patients with stable coronary heart disease. Methods: A total of 666 patients were enrolled and followed for 72 months. The primary outcome was a composite of cardiac events. The secondary outcomes were all-cause death, cardiovascular death, acute myocardial infarction (AMI), and heart failure hospitalization. Results: The area under the curve of tenascin-C to discriminate the occurrence of composite cardiac events was 70 % (95 % CI: 64.2 % to 75.8 %), and the corresponding optimal cutoff value was 19.91 ng/ml. A higher concentration of tenascin-C was associated with a greater risk of composite cardiac events (P trend < 0.001). Similar results were observed in all-cause death, AMI, and heart failure hospitalization. Conclusion: Tenascin-C was found to be an independent predictor of total cardiovascular events in patients with stable coronary heart disease at 72 months, and also for all-cause death, AMI, and heart failure hospitalization.

KW - Acute myocardial infarction

KW - Biomarker

KW - Cardiovascular outcome

KW - Stable coronary heart disease

KW - Tenascin-C

UR - http://www.scopus.com/inward/record.url?scp=85136495081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136495081&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2022.08.003

DO - 10.1016/j.cca.2022.08.003

M3 - Article

C2 - 35963306

AN - SCOPUS:85136495081

SN - 0009-8981

VL - 535

SP - 68

EP - 74

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

ER -

The prognostic significance of the presence of tenascin-C in patients with stable coronary heart disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this